1. Hepatic expression of SV40 small-T antigen blocks the in vivo CD95-mediated apoptosis.
- Author
-
Gillet R, Cavard C, Grimber G, Briand P, and Joulin V
- Subjects
- Animals, Antibodies, Monoclonal pharmacology, Antigens, Polyomavirus Transforming genetics, Antigens, Polyomavirus Transforming pharmacology, Blotting, Western, Cell Transformation, Neoplastic drug effects, Cell Transformation, Neoplastic genetics, Gene Expression, In Situ Nick-End Labeling, Kidney metabolism, Liver cytology, Liver drug effects, Mice, Mice, Transgenic, Mitosis drug effects, Mitosis genetics, Mutation, NF-kappa B metabolism, Phosphorylation drug effects, Protein Structure, Tertiary genetics, Proto-Oncogene Proteins metabolism, Proto-Oncogene Proteins c-akt, Signal Transduction drug effects, Transgenes, fas Receptor pharmacology, Antigens, Polyomavirus Transforming biosynthesis, Apoptosis drug effects, Liver metabolism, Protein Serine-Threonine Kinases, fas Receptor metabolism
- Abstract
We have previously demonstrated that CD95-mediated apoptosis of hepatocytes is blocked in a murine model of hepatocarcinogenesis due to the expression of SV40 early sequences encoding the large-T and small-t antigens. In this study, we set out to pinpoint the sequences involved in this apoptosis-resistant phenotype, and tested several mutants of the SV40 early region for their ability to confer protection against CD95-induced apoptosis in transgenic mice. We show that resistance to apoptosis is independent of the transforming character of the mutants and demonstrate that the expression of the small-t antigen alone in transgenic mice is sufficient to confer this resistance. Our data also reveal an increased level of activated Akt kinase in these transgenic mice, and this could account for this hitherto unknown function of the SV40 small-t antigen., (Copyright 2001 Academic Press.)
- Published
- 2001
- Full Text
- View/download PDF